Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kaye

Showing results (1141-1150 of 1,165) with videos related to

Pageof 117
Sort By:
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Heart Journal. Acute Cardiovascular Care|June 30, 2021
Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomesJason E Bloom, Emily Andrew, Ziad Nehme, et al.
Nature Communications|March 11, 2025
Integrated histopathology, spatial and single cell transcriptomics resolve cellular drivers of early and late alveolar damage in COVID-19Jimmy Tsz Hang Lee, Sam N Barnett, Kenny Roberts, et al.
Physical Review Letters|January 22, 2002
Characteristics of the first H-mode discharges in the national spherical torus experimentR Maingi, M G Bell, R E Bell, et al.
Circulation. Population Health and Outcomes|January 19, 2026
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF IIAndrew A Girard, Uma Mylavarapu, Jan Komtebedde, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Plos Neglected Tropical Diseases|February 27, 2026
Systemic inflammatory markers of visceral leishmaniasis treatment response in East AfricaAyenew Addisu, Alice Bayiyana, João L Reis Cunha, et al.
Pain Physician|November 20, 2024
Comprehensive Evidence-Based Guidelines for Implantable Peripheral Nerve Stimulation (PNS) in the Management of Chronic Pain: From the American Society Of Interventional Pain Physicians (ASIPP)Laxmaiah Manchikanti, Mahendra R Sanapati, Amol Soin, et al.
Pain Physician|February 6, 2019
Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) GuidelinesAnnu Navani, Laxmaiah Manchikanti, Sheri L Albers, et al.
Nature Methods|October 25, 2011
NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytesDavid A Elliott, Stefan R Braam, Katerina Koutsis, et al.
Pageof 117

Showing results (1141-1150 of 1,165) with videos related to

Sort By:
Pageof 117
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Heart Journal. Acute Cardiovascular Care|June 30, 2021
Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomesJason E Bloom, Emily Andrew, Ziad Nehme, et al.
Nature Communications|March 11, 2025
Integrated histopathology, spatial and single cell transcriptomics resolve cellular drivers of early and late alveolar damage in COVID-19Jimmy Tsz Hang Lee, Sam N Barnett, Kenny Roberts, et al.
Physical Review Letters|January 22, 2002
Characteristics of the first H-mode discharges in the national spherical torus experimentR Maingi, M G Bell, R E Bell, et al.
Circulation. Population Health and Outcomes|January 19, 2026
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF IIAndrew A Girard, Uma Mylavarapu, Jan Komtebedde, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Plos Neglected Tropical Diseases|February 27, 2026
Systemic inflammatory markers of visceral leishmaniasis treatment response in East AfricaAyenew Addisu, Alice Bayiyana, João L Reis Cunha, et al.
Pain Physician|November 20, 2024
Comprehensive Evidence-Based Guidelines for Implantable Peripheral Nerve Stimulation (PNS) in the Management of Chronic Pain: From the American Society Of Interventional Pain Physicians (ASIPP)Laxmaiah Manchikanti, Mahendra R Sanapati, Amol Soin, et al.
Pain Physician|February 6, 2019
Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) GuidelinesAnnu Navani, Laxmaiah Manchikanti, Sheri L Albers, et al.
Nature Methods|October 25, 2011
NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytesDavid A Elliott, Stefan R Braam, Katerina Koutsis, et al.
Pageof 117